MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, named Neoclease winner of its 2025 North American Advance Biotech Grant, providing access to M Lab™ Collaboration Center resources to advance our lead candidate, NCX-L2, for Parkinson's disease.
The grant gives our team hands-on access to expertise, technology, and facilities that will help move our lead program forward, from process development through the practical steps of translating an AI-designed nuclease toward the clinic.